FARALLON CAPITAL MANAGEMENT LLC
Q3 2026 Form 13-F
SAN FRANCISCO, CALIFORNIA
CIK 0000909661
· CRD 107322
· SEC-registered investment adviser
$23.2B Reported Value Total
FARALLON CAPITAL MANAGEMENT, L.L.C. reports 67 total accounts under management (AUM). There are 67 discretionary accounts valued at $52,076,899,000, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
71 funds
· $65.4B gross asset value
Hedge Fund: $65.4B
Source: Form ADV filed 2026-09-23
Reported value
$23.2B
Quarter over quarter
—
Holdings
—
Top-10 concentration
—
Filing Structure
Reports holdings for
- Farallon Capital Europe LLP · File #028-11719 · Q1 2014 – Q4 2024
- Farallon Capital Europe LLP (not a 13F filer in our records) · Q3 2021 – Q3 2021 · declared by one filing
- Farallon Capital Europe (not a 13F filer in our records) · Q1 2021 – Q2 2021 · declared by one filing
- FARALLON PARTNERS L L C/CA (not a 13F filer in our records) · File #028-06372 · Q2 2013 – Q4 2013
Key People
Form ADV owners & control persons
Andrew James Mclean Spokes
LIMITED PARTNER
Richard Pierre Bollini II
MANAGING MEMBER
Colby Trexler Clark
MANAGING MEMBER
Filing Navigation
Coverage begins with the second quarter of 2013. Earlier quarters are not shown while their accuracy is being verified.
13F Metrics
Loading 13F Metrics
Q3 2026 13F record
Q3 2026 13F filing summary
| Period of report | September 30, 2026 |
|---|---|
| Filed | November 16, 2026 |
| Form | 13F-HR |
| Reported value | $23.2B |
| Positions | 110 |
| Change in reported value | +0.7% |
| New positions | 48 |
| Exited positions | 23 |
| Position turnover | 53.4% |
| Top-10 concentration | 60.6% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q3 2026 13F
Filed Nov 16, 2026
|
110 | $23.2B |
|
Q2 2026 13F
Filed Aug 14, 2026
|
85 | $23.0B |
|
Q1 2026 13F
Filed May 15, 2026
|
170 | $20.5B |
|
Q4 2025 13F
Filed Feb 17, 2026
|
150 | $24.2B |
|
Q3 2025 13F
Filed Nov 14, 2025
|
139 | $24.4B |
|
Q2 2025 13F
Filed Aug 14, 2025
|
142 | $23.8B |
|
Q1 2025 13F
Filed May 15, 2025
|
144 | $20.9B |
|
Q4 2024 13F
Filed Feb 14, 2025
|
145 | $22.8B |
|
Q3 2024 13F
Filed Nov 14, 2024
|
158 | $22.8B |
|
Q2 2024 13F
Filed Aug 14, 2024
|
159 | $23.3B |
|
Q1 2024 13F
Filed May 15, 2024
|
168 | $23.6B |
|
Q4 2023 13F
Filed Feb 14, 2024
|
148 | $21.9B |
|
Q3 2023 13F
Filed Nov 14, 2023
|
153 | $61.0B |
|
Q2 2023 13F
Filed Aug 14, 2023
|
158 | $19.9B |
|
Q1 2023 13F
Filed May 15, 2023
|
177 | $33.5B |
|
Q4 2022 13F
Filed Feb 14, 2023
|
226 | $16.9B |
|
Q3 2022 13F
Filed Nov 14, 2022
|
288 | $18.2B |
|
Q2 2022 13F
Filed Aug 15, 2022
|
297 | $18.4B |
|
Q1 2022 13F
Filed May 16, 2022
|
305 | $20.7B |
|
Q4 2021 13F
Filed Feb 14, 2022
|
292 | $20.0B |
34 earlier quarters on file — choose one from the quarter menu above.
Top 20 holdings · Q3 2026
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | SPY P STATE STR SPDR S&P 500 ETF T | $4.0B | 17.15% |
| 2 | RVMD REVOLUTION MEDICINES INC | $2.8B | 11.87% |
| 3 | WBD WARNER BROS DISCOVERY INC | $1.5B | 6.58% |
| 4 | NTRA NATERA INC | $1.1B | 4.63% |
| 5 | BBIO BRIDGEBIO PHARMA INC | $937.5M | 4.04% |
| 6 | PTGX PROTAGONIST THERAPEUTICS INC | $907.0M | 3.91% |
| 7 | EXEL EXELIXIS INC | $858.3M | 3.7% |
| 8 | ROIV ROIVANT SCIENCES LTD | $795.2M | 3.43% |
| 9 | ROKU ROKU INC | $633.5M | 2.73% |
| 10 | AMZN AMAZON COM INC | $590.1M | 2.54% |
| 11 | GRAL GRAIL INC | $570.2M | 2.46% |
| 12 | BSX BOSTON SCIENTIFIC CORP | $492.7M | 2.12% |
| 13 | AVGO BROADCOM INC | $490.2M | 2.11% |
| 14 | CRH CRH PLC | $442.2M | 1.91% |
| 15 | KVUE KENVUE INC | $441.8M | 1.9% |
| 16 | TWST TWIST BIOSCIENCE CORP | $412.8M | 1.78% |
| 17 | UNH UNITEDHEALTH GROUP INC | $384.9M | 1.66% |
| 18 | MSFT MICROSOFT CORP | $376.2M | 1.62% |
| 19 | SNPS SYNOPSYS INC | $373.1M | 1.61% |
| 20 | KKR KKR & CO INC | $354.2M | 1.53% |
Values as reported on the Q3 2026 Form 13F. Every position is in the holdings table below.